Tags

Type your tag names separated by a space and hit enter

Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections.
Int J Antimicrob Agents. 2015 Sep; 46(3):266-71.IJ

Abstract

The rise in resistant Gram-negative bacteria is a major concern and has led to difficulty in treating multidrug-resistant (MDR) infections. Two recently approved combination antibiotics, ceftolozane/tazobactam and ceftazidime/avibactam, may be effective in treating these resistant infections. Ceftolozane is a novel cephalosporin that has been developed in combination with tazobactam, a recognised β-lactamase inhibitor (BLI). Avibactam is a novel BLI combined with ceftazidime, a cephalosporin with an established history. Both of these β-lactam/BLI combination agents have been shown to retain in vitro activity against selected resistant Gram-negative pathogens, including Enterobacteriaceae and Pseudomonas aeruginosa; notably, ceftazidime/avibactam has demonstrated consistent activity against Klebsiella pneumoniae carbapenemase (KPC)-producing organisms. Both agents have been approved for the indications of complicated intra-abdominal infection (with metronidazole) and complicated urinary tract infection, and have ongoing phase 3 trials for the treatment of ventilator-associated and nosocomial pneumonia. This manuscript will review current data available regarding the spectrum of activity and clinical trials that led to the US Food and Drug Administration (FDA) approval of these agents. Both agents appear to be well tolerated and show promise in the treatment of MDR Gram-negative infections.

Authors+Show Affiliations

Northeastern University, Boston, MA, USA.Beth Israel Deaconess Medical Center, Boston, MA, USA.Northeastern University, Boston, MA, USA; Beth Israel Deaconess Medical Center, Boston, MA, USA. Electronic address: e.hirsch@neu.edu.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

26143591

Citation

Liscio, Jordan L., et al. "Ceftolozane/tazobactam and Ceftazidime/avibactam: Two Novel Β-lactam/β-lactamase Inhibitor Combination Agents for the Treatment of Resistant Gram-negative Bacterial Infections." International Journal of Antimicrobial Agents, vol. 46, no. 3, 2015, pp. 266-71.
Liscio JL, Mahoney MV, Hirsch EB. Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections. Int J Antimicrob Agents. 2015;46(3):266-71.
Liscio, J. L., Mahoney, M. V., & Hirsch, E. B. (2015). Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections. International Journal of Antimicrobial Agents, 46(3), 266-71. https://doi.org/10.1016/j.ijantimicag.2015.05.003
Liscio JL, Mahoney MV, Hirsch EB. Ceftolozane/tazobactam and Ceftazidime/avibactam: Two Novel Β-lactam/β-lactamase Inhibitor Combination Agents for the Treatment of Resistant Gram-negative Bacterial Infections. Int J Antimicrob Agents. 2015;46(3):266-71. PubMed PMID: 26143591.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections. AU - Liscio,Jordan L, AU - Mahoney,Monica V, AU - Hirsch,Elizabeth B, Y1 - 2015/06/14/ PY - 2015/05/08/received PY - 2015/05/11/accepted PY - 2015/7/6/entrez PY - 2015/7/6/pubmed PY - 2016/5/24/medline KW - ESBL KW - KPC KW - Pseudomonas aeruginosa KW - cIAI KW - cUTI SP - 266 EP - 71 JF - International journal of antimicrobial agents JO - Int J Antimicrob Agents VL - 46 IS - 3 N2 - The rise in resistant Gram-negative bacteria is a major concern and has led to difficulty in treating multidrug-resistant (MDR) infections. Two recently approved combination antibiotics, ceftolozane/tazobactam and ceftazidime/avibactam, may be effective in treating these resistant infections. Ceftolozane is a novel cephalosporin that has been developed in combination with tazobactam, a recognised β-lactamase inhibitor (BLI). Avibactam is a novel BLI combined with ceftazidime, a cephalosporin with an established history. Both of these β-lactam/BLI combination agents have been shown to retain in vitro activity against selected resistant Gram-negative pathogens, including Enterobacteriaceae and Pseudomonas aeruginosa; notably, ceftazidime/avibactam has demonstrated consistent activity against Klebsiella pneumoniae carbapenemase (KPC)-producing organisms. Both agents have been approved for the indications of complicated intra-abdominal infection (with metronidazole) and complicated urinary tract infection, and have ongoing phase 3 trials for the treatment of ventilator-associated and nosocomial pneumonia. This manuscript will review current data available regarding the spectrum of activity and clinical trials that led to the US Food and Drug Administration (FDA) approval of these agents. Both agents appear to be well tolerated and show promise in the treatment of MDR Gram-negative infections. SN - 1872-7913 UR - https://www.unboundmedicine.com/medline/citation/26143591/Ceftolozane/tazobactam_and_ceftazidime/avibactam:_two_novel_β_lactam/β_lactamase_inhibitor_combination_agents_for_the_treatment_of_resistant_Gram_negative_bacterial_infections_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0924-8579(15)00203-4 DB - PRIME DP - Unbound Medicine ER -